This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALNA Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Allena Pharmaceuticals Stock (NASDAQ:ALNA) 30 days 90 days 365 days Advanced Chart Get Allena Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.02▼$0.1652-Week Range N/AVolume96,558 shsAverage Volume15.69 million shsMarket Capitalization$37 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Read More… Receive ALNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNA Stock News HeadlinesAllena Pharmaceuticals Inc ALNAQ Stock QuoteNovember 5, 2023 | morningstar.comAllena Pharmaceuticals Inc (ALNAQ)August 28, 2023 | investing.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.June 18, 2025 | Brownstone Research (Ad)San Francisco Pharmaceuticals NewsMay 6, 2023 | bizjournals.comALNA.OSeptember 29, 2022 | reuters.comFirm Retention Summary: Allena Pharmaceuticals Inc.September 6, 2022 | wsj.comAllena Pharmaceuticals Shares Fall After Filing For BankruptcySeptember 6, 2022 | finance.yahoo.comAllena Pharma Needs To Raise Capital To Continue As A Going ConcernAugust 11, 2022 | finance.yahoo.comSee More Headlines ALNA Stock Analysis - Frequently Asked Questions How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) announced its quarterly earnings data on Thursday, March, 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.06. When did Allena Pharmaceuticals IPO? Allena Pharmaceuticals (ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allena Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Zomedica (ZOM). Company Calendar Last Earnings3/31/2022Today6/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALNA CIK1624658 Webwww.allenapharma.com Phone(617) 467-4577Fax617-916-1871Employees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-287.46% Return on Assets-146.58% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / BookN/AMiscellaneous Outstanding Shares122,083,000Free Float117,566,000Market Cap$37 thousand OptionableNot Optionable Beta1.13 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ALNA) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allena Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.